ClinicalTrials.gg
CompletedNCT04530123Updated Nov 10, 2026Results posted

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

A Phase 2 interventional study of Placebo and TAK-101 in Celiac Disease, sponsored by Takeda. Completed at 48 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Takeda · Phase 2, Interventional, and Prevention

How we know

Updated Nov 10, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
20th of 68
102 · median 46
Started
2022
with 7 others
Phase 2
21 of 103
1 open now
Registered
73rd of 103
by date
Lead sponsor
6 of 103
Takeda

Among the 103 studies in Celiac Disease with a site in United States, this one is the 20th largest by enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2022, is one of 21 in phase 2, and was the 73rd registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD).

Participants will receive TAK-101 and/or placebo through the vein on Day 1 and Day 8. All participants will receive active treatment at Week 24.

Read the detailed description

The drug being tested in this study is called TAK-101. TAK-101 is being tested to treat people who have celiac disease. The study has 2 cohorts planned. Cohort 1 has 1 dose level and the Cohort 2 may include 1 or 2 additional dose levels, depending on safety, tolerability, and activity observed in Cohort 1. Dosing in the Cohort 2 will be based on data from Cohort 1.

The study will enroll approximately 90 patients. In Cohort 1, approximately 45 participants will be randomly assigned in 1:2:2 ratio in one of the three arm groups which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need). Eligible participants in Cohort 1 will receive:

  • Group A: 2 infusion doses of placebo, 1 infusion dose on Day 1 and 1 infusion dose on Day 8, followed by 1 infusion dose of 25 micrograms per kilogram (µg/kg) Gluten Epitopes (GE) TAK-101 at Week 24.
  • Group B: 1 infusion dose of 25 µg/kg GE TAK-101 on Day 1 followed by 1 infusion dose of placebo on Day 8, followed by 1 infusion dose of 25 µg/kg GE TAK-101 at Week 24.
  • Group C: 2 infusion doses of 25 µg/kg GE TAK-101, 1 infusion dose on Day 1 and 1 infusion dose on Day 8, followed by 1 infusion dose of 25 µg/kg GE TAK-101 at Week 24.

If it is deemed appropriate to enroll both the TAK-101 50 µg/kg GE and the 12.5 µg/kg GE dose levels in Cohort 2, approximately 45 participants may be randomly assigned in 1:2:2 ratio in Cohort 2 to receive:

  • Group A: Two infusion doses of placebo, 1 infusion dose on Day 1 and 1 infusion dose on Day 8, followed by 1 infusion dose of 25 µg/kg GE TAK-101 at Week 24.
  • Group D: Two infusion doses of 50 µg/kg GE TAK-101, 1 infusion dose on Day 1 and 1 infusion dose on Day 8, followed by 1 infusion dose of 50 µg/kg GE TAK-101 at Week 24.
  • Group F: Two infusion doses of 12.5 µg/kg GE TAK-101, 1 infusion dose on Day 1 and 1 infusion dose on Day 8, followed by 1 infusion dose of 12.5 µg/kg GE TAK-101 at Week 24.

If it is decided not to open the second cohort at the 50 µg/kg GE dose level and if 12.5 µg/kg GE dose is recommended to be tested by the independent data monitoring committee (IDMC), approximately 27 participants will be randomly assigned in 1:2 ratio to receive:

  • Group E: Two infusion doses of placebo, 1 infusion dose on Day 1 and 1 infusion dose on Day 8, followed by 1 infusion dose of 12.5 µg/kg GE TAK-101 at Week 24.
  • Group F: Two infusion doses of 12.5 µg/kg GE TAK-101, 1 infusion dose on Day 1 and 1 infusion dose on Day 8, followed by 1 infusion dose of 12.5 µg/kg TAK-101 at Week 24.

This trial will be conducted globally. The overall time to participate in this study is approximately 34 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone OR plus a final visit after receiving their last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Celiac Disease

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -confirmed CeD that is well-controlled, defined as mild or with no ongoing signs or symptoms felt to be related to active CeD and with immunoglobulin A (IgA) tissue transglutaminase (tTG) \<2 × (ULN) and IgG deamidated gliadin peptide (DGP) \<3 × ULN.

    Note: Participants may be retested for IgA tTG and IgG DGP to meet eligibility criteria at the discretion of the investigator. Intermittent symptoms would not exclude participants from participation as long as symptoms are generally well controlled in the opinion of the investigator, and as long as symptoms are back to baseline for 2 weeks before the run-in gluten challenge.

  2. Must be able to maintain a gluten-free diet (GFD) for ≥6 months.
  3. Must be HLA-DQ2.5 and/or HLA-DQ8 positive during screening laboratory testing.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 12 weeks (84 days) or 5 half-lives, whichever is longer, before signing of the form (ICF).
  2. Has received TAK-101 in a previous clinical study.
  3. Has presence of other inflammatory gastrointestinal (GI) disorders or systemic diseases, that either have the potential to cause persistent GI symptoms similar to CeD or are not well controlled without the use of excluded medications.

    • Examples of conditions that are exclusionary include: inflammatory bowel disease, eosinophilic gastroenteritis or colitis, and microscopic colitis requiring treatment in the 6 months before screening.
    • Examples of conditions that may be permissible after discussion with the medical monitor/or sponsor include: systemic autoimmune disease such as scleroderma, psoriatic or rheumatoid arthritis, lupus that is stable and without GI involvement, well controlled autoimmune thyroid disease, well controlled type 1 diabetes or proton pump inhibitor -responsive eosinophilic esophagitis in symptomatic and confirmed remission.
  4. Has known or suspected CeD or ulcerative jejunitis.
  5. Has known or suspected allergy to wheat, such as and/or anaphylaxis including wheat-dependent-exercise induced anaphylaxis (WDEIA). If there is a possible history of urticaria, angioedema, or anaphylaxis to wheat, investigators should perform testing for wheat anti-Immunoglobulin (anti-IgE) antibodies or refer to an allergist for evaluation prior to enrollment to rule out any of these allergies.
  6. Ongoing systemic , systemic (oral or IV) treatment, or has received treatment with systemic immunosuppressants or corticosteroids in the 12 weeks before run-in gluten challenge.
  7. Has known or suspected liver disease or positive test result for or C.
  8. Has intolerable symptoms after the run-in gluten challenge and is unwilling to undergo subsequent post treatment gluten challenges.
  9. Has known allergy to or intolerance of TAK-101 or any of its ingredients or . Also, any subject with a symptomatic allergic reaction that is confirmed by laboratory serology such as elevated tryptase levels following the administration of TAK-101 will be excluded from future dosing.
  10. Has a current diagnosis of active or malignancy diagnosed in the 5 years prior to screening or is receiving ongoing treatment for malignancy.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Cohort 1, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE

    Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 matching placebo intravenous (IV) infusion dose, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 microgram per kilogram (µg/kg) GE will be given 23 weeks after the second dose at approximately Week 24.

    Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten

  • Experimental
    Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE

    Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 25 µg/kg, IV infusion once on Day 1 followed by TAK-101 matching placebo IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24.

    Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten

  • Experimental
    Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE

    Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 25 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24.

    Drug: TAK-101 · Dietary Supplement: Gluten

  • Experimental
    Cohort 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE

    Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 matching placebo IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.

    Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten

  • Experimental
    Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE

    Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 50 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 50 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.

    Drug: TAK-101 · Dietary Supplement: Gluten

  • Experimental
    Cohort 2, Group E: Placebo + Placebo + TAK-101 12.5 µg/kg GE

    Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 12.5 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open Cohort 2 at the 50 µg/kg GE dose level.

    Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten

  • Experimental
    Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE

    Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 12.5 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 12.5 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.

    Drug: TAK-101 · Dietary Supplement: Gluten

Interventions

  • DrugPlacebo

    TAK-101 matching placebo intravenous infusion

  • TAK 101 intravenous infusion

  • Dietary supplementGlutensStudies of GlutensGlutens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Powder form (vital wheat gluten)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay

    IFN-γ SFUs were measured based on results of a gliadin-specific ELISpot assay using peripheral blood mononuclear cells (PBMCs). Gliadin-specific cluster of differentiation 4 (CD4) T cells were a small percentage of the PBMCs and responded to gliadin peptide stimulation in vitro by producing the IFN-γ cytokine. Baseline was defined as Day 15.

    Time frame: Baseline (Day 15), Week 3 (Day 20)

Secondary outcomes

  1. Percentage of Participants Experiencing at Least One Treatment-emergent Adverse Event (TEAE) and Adverse Events of Special Interest (AESIs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started, or severity worsened, or intensity increased after receiving the first study drug administration and up to within 30 days of last dose of study drug. An AESI (serious or nonserious) is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate. AESIs are reported based on the Standardized MedDRA Queries (SMQs) and based on case report forms (CRFs).

    Time frame: Up to Week 28

  2. Change From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD)

    CDSD version 2.1 is a 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of available daily scores recorded in 3 days prior and after the respective gluten challenge. Results are reported as least squares (LS) mean change from run-in at Weeks 8, 14 and 20, determined using a linear mixed-effect model for repeated measures (MMRM) analysis. A negative change from run-in indicates improvement.

    Time frame: Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20

  3. Change From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity Score

    CDSD version 2.1 is an 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of the available daily scores recorded in the 3 days prior and after the respective gluten challenge. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.

    Time frame: Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20

  4. Change From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity Score

    CDSD GI symptom severity score is an average of the daily GI symptom severity scores during the week. The daily GI symptom severity score is the average of the severity score for diarrhea, abdominal pain, bloating and nausea, ranging from 0 to 4. Symptom severity is evaluated using 5-point Likert-type scales (none, mild, moderate, severe, and very severe). Higher scores indicate more severe symptoms. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.

    Time frame: Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20

  5. Fold Change in Plasma Interleukin-2 (IL-2) From Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20

    The pre-gluten to 4 hours post-gluten challenge log transformed fold change in plasma IL-2 from Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20 were compared. Results are reported as LS mean change from run-in at Day 15, Weeks 8, 14 and 20, determined using a linear MMRM analysis.

    Time frame: Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20

  6. Fold Change in Plasma IL-2 at Specified Time Points

    The pre-gluten to 4 hours post-gluten challenge log-transformed fold change in plasma IL-2 at each of the time points is reported.

    Time frame: Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20

  7. Plasma Concentration of TAK-101 After Each Dose

    Free gliadin concentration in the plasma was measured and reported.

    Time frame: At end of infusion of Weeks 0, 1 and 24

  8. Serum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101

    ADA includes deamidated gliadin peptide- immunoglobulin G (DGP- IgG). Serum Concentration of ADAs was measured in Enzyme-Linked ImmunoAssay Units per milliliter denoted as EliA U/mL.

    Time frame: Predose at Weeks 1 and 24; and before gluten challenge at Weeks 2, 14, and 20

07

Results

Posted Oct 6, 2026

Participant flow

Participants took part in the study at various investigative sites globally from 23 June 2022 to 08 January 2026.

Participant flow — Overall Study
MilestoneCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Started2220212019
Completed2118191716
Not completed12233
Withdrew: Lost to follow-up10000
Withdrew: Withdrawal by subject01122
Withdrew: Reason not specified01111

Outcome measures

PrimaryChange From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay

IFN-γ SFUs were measured based on results of a gliadin-specific ELISpot assay using peripheral blood mononuclear cells (PBMCs). Gliadin-specific cluster of differentiation 4 (CD4) T cells were a small percentage of the PBMCs and responded to gliadin peptide stimulation in vitro by producing the IFN-γ cytokine. Baseline was defined as Day 15.

Time frame:
Baseline (Day 15), Week 3 (Day 20)
Reported as:
Mean · SFUs/10^6 cells PBMC
Change From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay
SFUs/10^6 cells PBMCCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Baseline2.2 ± 4.252.4 ± 4.611.9 ± 2.503.8 ± 5.243.9 ± 5.11
Change at Day 204.0 ± 14.391.3 ± 5.433.3 ± 8.773.3 ± 10.29-0.3 ± 5.70
Statistical analysis
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · Wilcoxon Rank Sum test · p = =0.745 · Median difference (final values): 0 · 95% CI -4.0 to 4.0
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · Wilcoxon Rank Sum test · p = =0.884 · Median difference (final values): 0 · 95% CI -2.0 to 4.0
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · Wilcoxon Rank Sum test · p = =0.707 · Median difference (final values): 0 · 95% CI -2.0 to 6.0
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · Wilcoxon Rank Sum test · p = =0.533 · Median difference (final values): -1 · 95% CI -4.0 to 2.0
SecondaryPercentage of Participants Experiencing at Least One Treatment-emergent Adverse Event (TEAE) and Adverse Events of Special Interest (AESIs)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started, or severity worsened, or intensity increased after receiving the first study drug administration and up to within 30 days of last dose of study drug. An AESI (serious or nonserious) is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate. AESIs are reported based on the Standardized MedDRA Queries (SMQs) and based on case report forms (CRFs).

Time frame:
Up to Week 28
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least One Treatment-emergent Adverse Event (TEAE) and Adverse Events of Special Interest (AESIs)
percentage of participantsCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Any TEAE81.894.785.795.084.2
AESI CRF4.521.114.315.042.1
AESI SMQ4.521.123.820.036.8
SecondaryChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD)

CDSD version 2.1 is a 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of available daily scores recorded in 3 days prior and after the respective gluten challenge. Results are reported as least squares (LS) mean change from run-in at Weeks 8, 14 and 20, determined using a linear mixed-effect model for repeated measures (MMRM) analysis. A negative change from run-in indicates improvement.

Time frame:
Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
Reported as:
Least squares mean · score on a scale
Change From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD)
score on a scaleCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Week 8-0.190 (-0.474 to 0.094)-0.081 (-0.357 to 0.195)-0.345 (-0.630 to -0.060)-0.017 (-0.358 to 0.324)-0.428 (-0.744 to -0.113)
Week 14-0.258 (-0.565 to 0.049)-0.196 (-0.471 to 0.080)-0.237 (-0.500 to 0.026)-0.136 (-0.477 to 0.204)-0.222 (-0.525 to 0.081)
Week 20-0.303 (-0.587 to -0.020)-0.128 (-0.427 to 0.170)-0.443 (-0.711 to -0.174)-0.151 (-0.634 to 0.333)-0.213 (-0.517 to 0.091)
Statistical analysis
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.571 (The analysis used a linear MMRM.) · Ls mean difference: 0.11 · 95% CI -0.272 to 0.491
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.424 (The analysis used a linear MMRM.) · Ls mean difference: -0.154 · 95% CI -0.535 to 0.227
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.413 (The analysis used a linear MMRM.) · Ls mean difference: 0.173 · 95% CI -0.244 to 0.591
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.248 (The analysis used a linear MMRM.) · Ls mean difference: -0.238 · 95% CI -0.643 to 0.168
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.756 (The analysis used a linear MMRM.) · Ls mean difference: 0.062 · 95% CI -0.334 to 0.458
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.913 (The analysis used a linear MMRM.) · Ls mean difference: 0.021 · 95% CI -0.358 to 0.400
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.578 (The analysis used a linear MMRM.) · Ls mean difference: 0.122 · 95% CI -0.310 to 0.553
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.861 (The analysis used a linear MMRM.) · Ls mean difference: 0.036 · 95% CI -0.373 to 0.445
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.382 (The analysis used a linear MMRM.) · Ls mean difference: 0.175 · 95% CI -0.219 to 0.569
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.454 (The analysis used a linear MMRM.) · Ls mean difference: -0.139 · 95% CI -0.507 to 0.228
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.578 (The analysis used a linear MMRM.) · Ls mean difference: 0.153 · 95% CI -0.388 to 0.693
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.653 (The analysis used a linear MMRM.) · Ls mean difference: 0.09 · 95% CI -0.306 to 0.486
SecondaryChange From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity Score

CDSD version 2.1 is an 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of the available daily scores recorded in the 3 days prior and after the respective gluten challenge. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.

Time frame:
Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
Reported as:
Least squares mean · score on a scale
Change From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity Score
score on a scaleCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Week 8-0.024 (-0.502 to 0.453)0.077 (-0.390 to 0.544)-0.347 (-0.828 to 0.133)0.007 (-0.514 to 0.527)-0.595 (-1.088 to -0.103)
Week 14-0.363 (-0.830 to 0.103)-0.063 (-0.540 to 0.414)-0.447 (-0.904 to 0.010)0.064 (-0.486 to 0.615)-0.195 (-0.688 to 0.297)
Week 20-0.637 (-1.115 to -0.159)-0.008 (-0.463 to 0.446)-0.656 (-1.113 to -0.200)-0.074 (-0.674 to 0.527)-0.262 (-0.754 to 0.230)
Statistical analysis
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.754 (The analysis used a linear MMRM.) · Ls mean difference: 0.101 · 95% CI -0.535 to 0.737
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.318 (The analysis used a linear MMRM.) · Ls mean difference: -0.323 · 95% CI -0.960 to 0.314
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.927 (The analysis used a linear MMRM.) · Ls mean difference: 0.031 · 95% CI -0.626 to 0.687
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.083 (The analysis used a linear MMRM.) · Ls mean difference: -0.571 · 95% CI -1.217 to 0.074
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.353 (The analysis used a linear MMRM.) · Ls mean difference: 0.3 · 95% CI -0.336 to 0.936
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.787 (The analysis used a linear MMRM.) · Ls mean difference: -0.084 · 95% CI -0.693 to 0.526
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.212 (The analysis used a linear MMRM.) · Ls mead difference: 0.428 · 95% CI -0.246 to 1.101
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.603 (The analysis used a linear MMRM.) · Ls mean difference: 0.168 · 95% CI -0.469 to 0.805
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.049 (The analysis used a linear MMRM.) · Ls mean difference: 0.628 · 95% CI 0.002 to 1.255
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.950 (The analysis used a linear MMRM.) · Ls mean difference: -0.02 · 95% CI -0.637 to 0.598
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.126 (The analysis used a linear MMRM.) · Ls mean difference: 0.563 · 95% CI -0.159 to 1.286
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.253 (The analysis used a linear MMRM.) · Ls mean difference: 0.375 · 95% CI -0.271 to 1.021
SecondaryChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity Score

CDSD GI symptom severity score is an average of the daily GI symptom severity scores during the week. The daily GI symptom severity score is the average of the severity score for diarrhea, abdominal pain, bloating and nausea, ranging from 0 to 4. Symptom severity is evaluated using 5-point Likert-type scales (none, mild, moderate, severe, and very severe). Higher scores indicate more severe symptoms. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.

Time frame:
Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
Reported as:
Least squares mean · score on a scale
Change From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity Score
score on a scaleCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Week 8-0.067 (-0.212 to 0.077)-0.035 (-0.168 to 0.098)-0.155 (-0.297 to -0.013)-0.112 (-0.266 to 0.042)-0.092 (-0.236 to 0.053)
Week 14-0.117 (-0.257 to 0.022)0.064 (-0.076 to 0.204)-0.093 (-0.231 to 0.045)-0.173 (-0.337 to -0.009)-0.122 (-0.271 to 0.027)
Week 20-0.213 (-0.353 to -0.073)0.028 (-0.105 to 0.161)-0.159 (-0.300 to -0.018)-0.187 (-0.367 to -0.006)-0.061 (-0.206 to 0.083)
Statistical analysis
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.735 (The analysis used a linear MMRM.) · Ls mean difference: 0.032 · 95% CI -0.156 to 0.221
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.374 (The analysis used a linear MMRM.) · Ls mean difference: -0.087 · 95% CI -0.281 to 0.106
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.661 (The analysis used a linear MMRM.) · Ls mean difference: -0.044 · 95% CI -0.244 to 0.155
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.805 (The analysis used a linear MMRM.) · Ls mean difference: -0.024 · 95% CI -0.218 to 0.170
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.061 (The analysis used a linear MMRM.) · Ls mean difference: 0.182 · 95% CI -0.009 to 0.372
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.796 (The analysis used a linear MMRM.) · Ls mean difference: 0.025 · 95% CI -0.162 to 0.211
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.594 (The analysis used a linear MMRM.) · Ls mean difference: -0.055 · 95% CI -0.260 to 0.149
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.965 (The analysis used a linear MMRM.) · Ls mean difference: -0.004 · 95% CI -0.199 to 0.190
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.011 (The analysis used a linear MMRM.) · Ls mean difference: 0.241 · 95% CI 0.056 to 0.426
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.576 (The analysis used a linear MMRM.) · Ls mean difference: 0.054 · 95% CI -0.135 to 0.243
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.811 (The analysis used a linear MMRM.) · Ls mean difference: 0.026 · 95% CI -0.191 to 0.244
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.119 (The analysis used a linear MMRM.) · Ls mean difference: 0.152 · 95% CI -0.039 to 0.343
SecondaryFold Change in Plasma Interleukin-2 (IL-2) From Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20

The pre-gluten to 4 hours post-gluten challenge log transformed fold change in plasma IL-2 from Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20 were compared. Results are reported as LS mean change from run-in at Day 15, Weeks 8, 14 and 20, determined using a linear MMRM analysis.

Time frame:
Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
Reported as:
Least squares mean · log (fold change)
Fold Change in Plasma Interleukin-2 (IL-2) From Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20
log (fold change)Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Week 21.013 (0.491 to 1.535)1.121 (0.565 to 1.678)0.600 (0.076 to 1.124)1.757 (1.199 to 2.315)0.723 (0.141 to 1.305)
Week 8-0.322 (-0.861 to 0.216)-0.247 (-0.814 to 0.320)-0.805 (-1.329 to -0.281)-0.551 (-1.137 to 0.034)-0.891 (-1.487 to -0.296)
Week 14-0.289 (-0.819 to 0.240)-0.430 (-0.986 to 0.126)-0.521 (-1.073 to 0.030)0.422 (-0.168 to 1.011)-0.688 (-1.283 to -0.094)
Week 20-0.475 (-1.004 to 0.054)-0.593 (-1.149 to -0.037)-0.644 (-1.194 to -0.095)0.043 (-0.571 to 0.657)-0.503 (-1.110 to 0.103)
Statistical analysis
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.768 (The analysis used a linear MMRM.) · Ls mean difference: 0.108 · 95% CI -0.615 to 0.832
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.243 (The analysis used a linear MMRM.) · Ls mean difference: -0.413 · 95% CI -1.109 to 0.282
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.041 (The analysis used a linear MMRM.) · Ls mean difference: 0.744 · 95% CI 0.031 to 1.457
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.438 · Ls mean difference: -0.29 · 95% CI -1.026 to 0.446
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.842 · Ls mean difference: 0.076 · 95% CI -0.670 to 0.821
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.181 · Ls mean difference: -0.482 · 95% CI -1.191 to 0.227
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.545 · Ls mean difference: -0.229 · 95% CI -0.973 to 0.515
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.141 · Ls mean difference: -0.569 · 95% CI -1.328 to 0.190
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.705 · Ls mean difference: -0.14 · 95% CI -0.870 to 0.589
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.529 · Ls mean difference: -0.232 · 95% CI -0.956 to 0.492
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.062 · Ls mean difference: 0.711 · 95% CI -0.035 to 1.457
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.296 · Ls mean difference: -0.399 · 95% CI -1.150 to 0.352
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE · MMRM · p = =0.750 · Ls mean difference: -0.118 · 95% CI -0.847 to 0.611
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE · MMRM · p = =0.644 · Ls mean difference: -0.169 · 95% CI -0.891 to 0.552
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE · MMRM · p = =0.184 · Ls mean difference: 0.517 · 95% CI -0.248 to 1.283
  • Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE vs Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE · MMRM · p = =0.941 · Ls mean difference: -0.028 · 95% CI -0.790 to 0.733
SecondaryFold Change in Plasma IL-2 at Specified Time Points

The pre-gluten to 4 hours post-gluten challenge log-transformed fold change in plasma IL-2 at each of the time points is reported.

Time frame:
Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
Reported as:
Mean · log (fold change)
Fold Change in Plasma IL-2 at Specified Time Points
log (fold change)Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Run-in (Week -4)2.15 ± 1.4352.12 ± 1.4252.47 ± 1.9472.58 ± 1.8941.75 ± 2.067
Week 23.16 ± 1.3593.26 ± 1.6572.97 ± 1.6004.16 ± 2.3102.54 ± 2.046
Week 81.82 ± 1.1951.97 ± 0.9891.56 ± 1.3051.93 ± 2.2401.00 ± 1.424
Week 141.78 ± 1.3261.71 ± 1.4501.87 ± 1.6802.50 ± 1.8291.21 ± 1.512
Week 201.63 ± 1.4031.54 ± 1.0681.76 ± 1.2882.10 ± 1.7791.31 ± 1.433
SecondaryPlasma Concentration of TAK-101 After Each Dose

Free gliadin concentration in the plasma was measured and reported.

Time frame:
At end of infusion of Weeks 0, 1 and 24
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of TAK-101 After Each Dose
nanograms per milliliter (ng/mL)Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Week 0NA ± NA574.89 ± 104.544551.21 ± 101.606257.45 ± 61.830913.56 ± 261.678
Week 1NA ± NANA ± NA423.79 ± 161.542195.54 ± 78.827848.06 ± 256.314
Week 24585.23 ± 90.526613.72 ± 176.414601.22 ± 142.565289.31 ± 67.8121171.75 ± 157.166
SecondarySerum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101

ADA includes deamidated gliadin peptide- immunoglobulin G (DGP- IgG). Serum Concentration of ADAs was measured in Enzyme-Linked ImmunoAssay Units per milliliter denoted as EliA U/mL.

Time frame:
Predose at Weeks 1 and 24; and before gluten challenge at Weeks 2, 14, and 20
Reported as:
Mean · EliA U/mL
Serum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101
EliA U/mLCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
Week 1 (Day 8)1.86 ± 3.4822.94 ± 3.1733.88 ± 6.7322.75 ± 3.2313.18 ± 4.006
Week 2 (Day 15)1.69 ± 2.7043.17 ± 3.3696.98 ± 12.5396.83 ± 8.08212.20 ± 23.588
Week 142.05 ± 2.8423.72 ± 5.2985.10 ± 8.78411.22 ± 28.12610.63 ± 27.621
Week 202.30 ± 2.6382.45 ± 3.0565.06 ± 9.1446.17 ± 10.9296.90 ± 15.418
Week 242.37 ± 2.3483.97 ± 6.4284.57 ± 8.6085.12 ± 9.1644.47 ± 8.632

Adverse events

Collected over Up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE0/22 (0%)0/22 (0%)17/22 (77.3%)
Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE0/20 (0%)0/19 (0%)18/19 (94.7%)
Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE0/21 (0%)0/21 (0%)17/21 (81%)
Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE0/20 (0%)0/20 (0%)15/20 (75%)
Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE0/19 (0%)0/19 (0%)16/19 (84.2%)
Most frequent other events
Showing 10 of 78
Most frequent other events
EventCohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE
NAUSEAGastrointestinal disorders7/225/194/216/203/19
HEADACHENervous system disorders4/226/192/214/201/19
DIARRHOEAGastrointestinal disorders3/225/192/210/205/19
INFUSION RELATED REACTIONInjury, poisoning and procedural complications1/222/193/213/205/19
FATIGUEGeneral disorders1/223/194/215/204/19
THROMBIN-ANTITHROMBIN III COMPLEX INCREASEDInvestigations2/224/191/214/201/19
ABDOMINAL DISTENSIONGastrointestinal disorders3/223/191/212/200/19
FIBRIN D DIMER INCREASEDInvestigations0/223/190/211/201/19
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders1/223/190/210/201/19
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/223/192/213/201/19

Baseline characteristics

All Randomized Set consisted of all the participants who were randomized.

Age, Continuous
Age, Continuous(years)Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GETotal
Mean42.8 ± 12.6446.4 ± 14.6343.1 ± 13.3547.4 ± 11.7241.3 ± 11.8444.2 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GETotal
Female13171391365
Male93811637
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GETotal
Hispanic or Latino110002
Not Hispanic or Latino201820201997
Unknown or Not Reported111003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GECohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GECohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GECohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GECohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GETotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000101
White192021171996
More than one race100203
Unknown or Not Reported200002
08

Study locations

48 sites
  • One of a Kind Clinical Research Center LLC
    Scottsdale, Arizona 85258, United States
  • Gastroenterology and Liver Institute
    Escondido, California 92025, United States
  • Cadena Care Institute, Inc.
    Poway, California 92064, United States
  • Asthma and Allergy Associates, PC
    Colorado Springs, Colorado 80907, United States
  • GCP Clinical Research, LLC
    Tampa, Florida 33609, United States
  • Agile Clinical Research Trials
    Atlanta, Georgia 30328, United States
  • Lemah Creek Clinical Research
    Burr Ridge, Illinois 60527, United States
  • Gastroenterology Associates, PA
    Rockford, Illinois 61107, United States
  • Rockford Gastroenterology Associates, Ltd.
    Rockford, Illinois 61107, United States
  • Berkshire Medical Center
    New Albany, Indiana 47150, United States
  • Gastroenterology Health Partners, PLLC
    New Albany, Indiana 47150, United States
  • Boston Specialists
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Berkshire Medical Center, Inc.
    Pittsfield, Massachusetts 01201, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48048, United States
  • Wellness Clinical Research
    Chesterfield, Michigan 48048, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Basil Clinical
    Inwood, New York 11096, United States
  • Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center. New York Presbyterian Hospital
    New York, New York 10032, United States
  • East Carolina Gastroenterology, PA
    Jacksonville, North Carolina 28546, United States
  • GI Alliance-Rhode Island
    Providence, Rhode Island 02904, United States
  • Amel Med LLC
    Georgetown, Texas 78628, United States
  • Care Access Research - Salt Lake City
    Ogden, Utah 84403, United States
  • Royal Melbourne Hospital
    Parkville, AU VIC 3050, Australia
  • Emeritus Research, Sydney
    Botany, NS NSW 2019, Australia
  • Coral Sea Clinical Research Institute
    North Mackay, Queensland QLD 4740, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland QLD 4102, Australia
  • Emeritus Research, Melbourne
    Camberwell, Victoria VIC 3124, Australia
  • The Northern Hospital
    Epping, Victoria VIC 3076, Australia
  • St John of God Midland
    Midland, Western Australia 6056, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, VIC 3065, Australia
  • Mater Hospital Brisbane
    South Brisbane, QLD 4101, Australia
  • Gastroenterology and Internal Medicine Research Institute (GIRI)
    Edmonton, Alberta T5R 1W2, Canada
  • PerCuro Clinical Research Ltd.
    Victoria, British Columbia V8V 3M9, Canada
  • McMaster University
    Hamilton, Ontario L8S4K1, Canada
  • Scott Shulman Medicine Professional Corporation
    North Bay, Ontario P1B 2H3, Canada
  • DIEX Recherche Quebec Inc.
    Québec, Quebec G1V 4T3, Canada
  • Silverdale Medical
    Silverdale, Auckland 930, New Zealand
  • Optimal Clinical Trials - North
    Auckland, AU 632, New Zealand
  • Southern Clinical Trials Totara
    New Lynn, AU 1016, New Zealand
  • Momentum Clinical Research Dunedin
    Dunedin, OT 90160, New Zealand
  • P3 Research Limited (Wellington)
    Wellington, OT 6021, New Zealand
  • Capital, Coast and Hutt Valley - Wellington Regional Hospital
    Boulcott, WG 5010, New Zealand
  • Lakeland Clinical Trials Wellington
    Upper Hutt, WG 5018, New Zealand
  • Optimal Clinical Trials - Central
    Grafton, 1010, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Dec 2025, 41 months.

Results were first posted in Oct 2026, 9 months after primary completion.

Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Aug 28, 2020
StartActual
Jun 23, 2022
Primary completionActual
Dec 9, 2025
CompletionActual
Jan 8, 2026
Results first posted
Oct 6, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 6, 2026 · revised Nov 10, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameChange From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) AssayBaseline (Day 15, or Day 1 in the absence of Day 15) to Week 3 (Day 20) → Baseline (Day 15), Week 3 (Day 20)
  • DescriptionChange From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay: how it is measured was reworded
Oct 6, 2026
Documents
Secondary outcomes
2 edited, 6 time frame changed, 6 description edited
What changed in the outcomes
  • EditedPercentage of Participants Experiencing at Least One Treatment-emergent Adverse Event (AETEAE) and Adverse Events of Special Interest (AESIs)Time frame: From the first IV dose up to 30 days after last IV dose (Up to Week 28) → Up to Week 28
  • EditedFold Change in Plasma Interleukin-2 (IL-2) fromFrom Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20Time frame: Pre-/post-gluten challenge at Run-in (Visit 2), Day 15, and Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
  • Time frameChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD)Run-in (Visit 2), Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
  • Time frameChange From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity ScoreRun-in (Visit 2), Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
  • Time frameChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity ScoreRun-in (Visit 2), Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
  • Time frameFold Change in Plasma IL-2 at Specified Time PointsPre-/post-gluten challenge at Run-in (Visit 2), Day 15, and Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
  • Time framePlasma Concentration of TAK-101 After Each DosePredose and postdose at Weeks 0, 1 and 24 → At end of infusion of Weeks 0, 1 and 24
  • Time frameSerum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101Predose at Week 1 and before gluten challenge at Weeks 2, 14, 20, and 24 → Predose at Weeks 1 and 24; and before gluten challenge at Weeks 2, 14, and 20
  • DescriptionChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity Score: how it is measured was reworded
  • DescriptionChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD): how it is measured was reworded
  • DescriptionChange From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity Score: how it is measured was reworded
  • DescriptionFold Change in Plasma IL-2 at Specified Time Points: how it is measured was reworded
  • DescriptionPlasma Concentration of TAK-101 After Each Dose: how it is measured was reworded
  • DescriptionSerum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101: how it is measured was reworded
Oct 6, 2026
Show all 2 updates
  1. Nov 10, 2026
    Posted results revised
    + 2 other changes: verification date and contact details
  2. Oct 6, 2026
    Results posted
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameChange From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) AssayBaseline (Day 15, or Day 1 in the absence of Day 15) to Week 3 (Day 20) → Baseline (Day 15), Week 3 (Day 20)
    • DescriptionChange From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay: how it is measured was reworded
    Secondary outcomes 2 edited, 6 time frame changed, 6 description edited
    What changed in the outcomes
    • EditedPercentage of Participants Experiencing at Least One Treatment-emergent Adverse Event (AETEAE) and Adverse Events of Special Interest (AESIs)Time frame: From the first IV dose up to 30 days after last IV dose (Up to Week 28) → Up to Week 28
    • EditedFold Change in Plasma Interleukin-2 (IL-2) fromFrom Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20Time frame: Pre-/post-gluten challenge at Run-in (Visit 2), Day 15, and Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
    • Time frameChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD)Run-in (Visit 2), Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
    • Time frameChange From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity ScoreRun-in (Visit 2), Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
    • Time frameChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity ScoreRun-in (Visit 2), Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
    • Time frameFold Change in Plasma IL-2 at Specified Time PointsPre-/post-gluten challenge at Run-in (Visit 2), Day 15, and Weeks 8, 14, and 20 → Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
    • Time framePlasma Concentration of TAK-101 After Each DosePredose and postdose at Weeks 0, 1 and 24 → At end of infusion of Weeks 0, 1 and 24
    • Time frameSerum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101Predose at Week 1 and before gluten challenge at Weeks 2, 14, 20, and 24 → Predose at Weeks 1 and 24; and before gluten challenge at Weeks 2, 14, and 20
    • DescriptionChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity Score: how it is measured was reworded
    • DescriptionChange From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD): how it is measured was reworded
    • DescriptionChange From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity Score: how it is measured was reworded
    • DescriptionFold Change in Plasma IL-2 at Specified Time Points: how it is measured was reworded
    • DescriptionPlasma Concentration of TAK-101 After Each Dose: how it is measured was reworded
    • DescriptionSerum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101: how it is measured was reworded
    + 5 other changes: verification date, description, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04530123
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Jun 23, 2022
Primary completion
Dec 9, 2025
Completion
Jan 8, 2026
Results posted
Oct 6, 2026
Last update
Nov 10, 2026

Study contacts

Medical Director
study director · Takeda (Note: This product was divested to COUR Pharmaceutical Development Company, Inc. in 2026)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-101

Start the discussion